Takeda acquired the drug as part of its $62 ... including congenital thrombotic thrombocytopenic purpura (cTTP) therapy Adzynma (ADAMTS13, recombinant) and immune globulin-based products Hyqvia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback